MedTrace Logo

Daily Versus Twice Per Day Tamsulosin for Ureteral Stent Symptoms

NCT03799120 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2019-02-25

No results posted yet for this study

Summary

A single-center prospective, randomized study to assess two different dosing regimens (0.4 mg QD vs. 0.4 mg BID) of tamsulosin for ureteral stent-related discomfort will be completed.

Conditions

  • Ureteral Diseases

Interventions

DRUG

Tamsulosin BID

comparison of once daily versus twice daily tamsulosin

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Gundersen Lutheran Medical Foundation

    lead OTHER

Principal Investigators

  • Matthew Ferroni, MD · Gundersen Health System

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-18
Primary Completion
2021-12-31
Completion
2021-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03799120 on ClinicalTrials.gov